Salarius Pharmaceuticals Files 8-K/A Amendment
Ticker: DCOY · Form: 8-K/A · Filed: Aug 26, 2025 · CIK: 1615219
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
Salarius Pharma amended its 8-K filing on Aug 26, 2025, related to financial statements and exhibits from Aug 22, 2025.
AI Summary
Salarius Pharmaceuticals, Inc. filed an 8-K/A on August 26, 2025, to amend a previous filing. The amendment pertains to financial statements and exhibits, with the earliest event reported on August 22, 2025. The company, formerly known as Flex Pharma, Inc., is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information, which could be important for investors to review for the most accurate company data.
Risk Assessment
Risk Level: low — This is a routine amendment to a previous filing, not indicating new material events or financial distress.
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- Flex Pharma, Inc. (company) — Former company name
- August 22, 2025 (date) — Date of earliest event reported
- August 26, 2025 (date) — Filing date
FAQ
What is the purpose of this 8-K/A filing?
The purpose of this 8-K/A filing is to amend a previous report, specifically concerning financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 22, 2025.
What is the filing date of this 8-K/A?
This 8-K/A was filed on August 26, 2025.
What is the former name of Salarius Pharmaceuticals, Inc.?
The former name of Salarius Pharmaceuticals, Inc. was Flex Pharma, Inc.
Where is Salarius Pharmaceuticals, Inc. headquartered?
Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-08-26 16:07:39
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi
Filing Documents
- flks-20250822.htm (8-K/A) — 29KB
- exhibit993-8xka.htm (EX-99.3) — 374KB
- 0001615219-25-000115.txt ( ) — 551KB
- flks-20250822.xsd (EX-101.SCH) — 2KB
- flks-20250822_lab.xml (EX-101.LAB) — 22KB
- flks-20250822_pre.xml (EX-101.PRE) — 13KB
- flks-20250822_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.3 Unaudited Pro Forma Balance Sheet as of June 30, 2025 and Statement of Operations of Salarius Pharmaceuticals, Inc. and Decoy Therapeutics Inc. as of June 30, 2025 and December 31, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: August 26, 2025 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Acting Chief Executive Officer, Executive Vice President & Chief Financial Officer